Researchers at Karolinska Institutet have discovered new insights into brain changes in Parkinson's disease using advanced ...

BIIB143, also known as cemdomespib, was the most advanced asset to get the chop. Biogen acquired the Hsp90 modulator in 2023 through its buyout of Reata, a deal that centered on the FDA-approved ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, ...

A grant from the Alzheimer’s Foundation of America will be used to purchase equipment to serve families affected by ...

A nutritionist has sounded the alarm after research revealed that millions of Brits are not getting enough of a crucial ...

New research uncovers how declining protein clearance mechanisms with age lead to Alzheimer’s, Parkinson’s, and other ...

From a study that analyzed brain images of more than 2,500 people with Parkinson's disease in 20 different countries, scientists were able to identify patterns of neurodegeneration and create metrics ...

The study may suggest that other researchers should be less optimistic about the prospects for treating a range of other ...

VERO BEACH — The Alzheimer’s Foundation of America has awarded a grant to the Alzheimer & Parkinson Association of Indian River County to expand its Project Lifesaver program, which provides ...

Exenatide had no disease-modifying effects in a phase 3 trial Parkinson’s disease, despite earlier evidence from a phase 2 ...

Bishop asked about upcoming events. Missling outlined the anticipated schizophrenia trial readout for ANAVEX 3-71 in the first half of 2025, the detailed ATTENTION-AD data presentation in April, and ...

The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.